Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597012 | 0.95 | FPR2 (0.44) | USP30PIK3CAPIK3R1FPR2HDAC4 | |
| SCHEMBL5597056 | 0.94 | TP53 (0.41) | FPR2GPR119TP53 | |
| SCHEMBL5596812 | 0.89 | PIK3CA (0.45) | USP30PIK3CAPIK3R1SRCEGFR | |
| SCHEMBL5597039 | 0.84 | FPR2 (0.41) | USP30PIK3CAPIK3R1SRCFPR2 | |
| SCHEMBL5596990 | 0.83 | USP30 (0.40) | USP30PIK3CAPIK3R1SRCFPR2 | |
| SCHEMBL5596448 | 0.83 | TP53 (0.41) | PIK3CAPIK3R1SRCEGFRGPR119 | |
| SCHEMBL5596878 | 0.83 | USP30 (0.47) | USP30PIK3CAPIK3R1SRCEGFR | |
| SCHEMBL5597227 | 0.81 | USP30 (0.42) | USP30PIK3CAPIK3R1SRCFPR2 | |
| SCHEMBL5596649 | 0.81 | FPR2 (0.43) | FPR2GPR119 | |
| SCHEMBL5596376 | 0.78 | FPR2 (0.44) | USP30PIK3CAPIK3R1FPR2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | USP30 3669/4885PIK3CA 1188/4885PIK3R1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.